FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1996935761> ?p ?o ?g. }

• W1996935761 endingPage "166" @default.
• W1996935761 startingPage "165" @default.
• W1996935761 abstract "To the Editor, Pulmonary arterial hypertension (PAH) is an uncommon adverse effect of tyrosine kinase inhibitor. The article by Montani et al. [1] demonstrated PAH in patients treated with dasatinib. We report a 33-year-old male with chronic myeloid leukemia who suffered from shortness of breath after using dasatinib for 63 months. Noninvasive echocardiographic assessment revealed reversible PAH corresponding to clinical manifestations. In October 2013, the patient presented with progressive dyspnea on exertion. He was known to have chronic phase chronic myeloid leukemia since January 1998. The initial laboratory data revealed eosinophilia, basophilia, low leukocyte alkaline phosphatase score, and positive BCR-ABL gene. He was initially treated with hydroxyurea 1000 mg twice per day, and then commenced imatinib at 800 mg/day since May 2002. Under imatinib use, hematological complete remission was achieved, but there was no cytogenetic remission with a positive b2a2 BCR-ABL mutation. Point mutation in the kinase domain of BCR-ABL with F359V was identified. Imatinib was shifted to dasatinib 100 mg/day in July 2008 and a major molecular response was achieved. However, the patient suffered from progressive dyspnea in October 2013. The auscultation showed bilateral clear breathing sound. Prominence of bilateral hilar shadows were present on chest plain film (Fig. 1A). No thromboembolism evidence existed but dilatation of pulmonary trunk and proximal arteries in the chest computed tomography scan was found (Fig. 1B). Tc-99m DTPA (Diethylenetriamine pentaacetate) aerosol ventilation and Tc-99m MMA (microaggregated albulin) perfusion scintigraphy revealed a V (ventilation)/Q (perfusion) match reduction of the pulmonary functional volume. Doppler transthoracic echocardiography showed severe pulmonary arterial hypertension with an estimated pulmonary artery systolic pressure (PASP) of 105 mmHg, right atrial and right ventricular dilatation, and severe tricuspid regurgitation (Fig. 1C and D). We stopped using dasatinib but the symptoms persisted. One month later, we added on phosphodiesterase type 5 (PDE 5) inhibitor, sildenafil, and the symptoms improved gradually. Echocardiography was followed 3months later and estimated PASP regressed back to 45 mmHg (Fig. 1E). Dasatinib was replaced by nilotinib in this patient. Characteristic image findings of reversible dasatinib-related pulmonary arterial hypertension. (A and B) Tc-99m DTPA (diethylenetriamine pentaacetate) aerosol ventilation and Tc-99m MMA (microaggregated albulin) perfusion scintigraphy reveals V (ventilation)/Q (perfusion) match reduction of pulmonary functional volume; (C and D) Doppler transthoracic echocardiography shows severe pulmonary arterial hypertension with estimated PASP 105 mmHg; (E); after stopping dasatinib and adding sildenafil, the estimated PASP fell back to 45 mmHg. PASP = pulmonary artery systolic pressure. Pulmonary arterial hypertension (PAH) is defined as the mean pulmonary artery pressure (PAP) of >25 mmHg at rest, or >30 mmHg during exercise [2]. The definite diagnosis includes invasive right heart catheterization. However, there is a good correlation between transthoracic echocardiography and right heart catheterization measurement of PASP [3]. PAH is suspected if noninvasive PASP, determined by tricuspid regurgitation peak gradient (TRPG) and right atrial pressure(RAP) according to the simplified Bernoulli equation, is >35 mmHg measured by Doppler transthoracic echocardiography [2]. In 2007, a study by Quintás-Cardama et al. [4] suggested the association between dasatinib and pulmonary hypertension. In 2012, nine cases of symptomatic pulmonary hypertension treated with dasatinib have been identified definitely [1]. PAH appears as a late complication of dasatinib, occurring after 8–48 months of exposure [5]. The possible mechanism is dasatinib served as multi tyrosine kinase inhibitors, including BCR-ABL, SRC, c-kit, and PDGFR [5]. Symptoms are improved after discontinuation of dasatinib in the majority of cases, but some cases require PAH-specific therapy with sildenafil [5]. In summary, we reported a typical case of dasatinib-induced PAH diagnosed by noninvasive echocardiography." @default.
• W1996935761 created "2016-06-24" @default.
• W1996935761 creator A5005075670 @default.
• W1996935761 creator A5023758818 @default.
• W1996935761 creator A5089886091 @default.
• W1996935761 date "2015-03-01" @default.
• W1996935761 modified "2023-10-16" @default.
• W1996935761 title "Reversible dasatinib-related pulmonary arterial hypertension diagnosed by noninvasive echocardiography" @default.
• W1996935761 cites W2070507117 @default.
• W1996935761 cites W2083565359 @default.
• W1996935761 cites W2107610389 @default.
• W1996935761 cites W2126579741 @default.
• W1996935761 cites W2129125190 @default.
• W1996935761 doi "https://doi.org/10.1016/j.kjms.2014.11.010" @default.
• W1996935761 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25744241" @default.
• W1996935761 hasPublicationYear "2015" @default.
• W1996935761 type Work @default.
• W1996935761 sameAs 1996935761 @default.
• W1996935761 citedByCount "4" @default.
• W1996935761 countsByYear W19969357612015 @default.
• W1996935761 countsByYear W19969357612017 @default.
• W1996935761 countsByYear W19969357612018 @default.
• W1996935761 countsByYear W19969357612021 @default.
• W1996935761 crossrefType "journal-article" @default.
• W1996935761 hasAuthorship W1996935761A5005075670 @default.
• W1996935761 hasAuthorship W1996935761A5023758818 @default.
• W1996935761 hasAuthorship W1996935761A5089886091 @default.
• W1996935761 hasBestOaLocation W19969357611 @default.
• W1996935761 hasConcept C126322002 @default.
• W1996935761 hasConcept C164705383 @default.
• W1996935761 hasConcept C2777583451 @default.
• W1996935761 hasConcept C2778729363 @default.
• W1996935761 hasConcept C2779536868 @default.
• W1996935761 hasConcept C2780930700 @default.
• W1996935761 hasConcept C3019892230 @default.
• W1996935761 hasConcept C71924100 @default.
• W1996935761 hasConcept C90924648 @default.
• W1996935761 hasConceptScore W1996935761C126322002 @default.
• W1996935761 hasConceptScore W1996935761C164705383 @default.
• W1996935761 hasConceptScore W1996935761C2777583451 @default.
• W1996935761 hasConceptScore W1996935761C2778729363 @default.
• W1996935761 hasConceptScore W1996935761C2779536868 @default.
• W1996935761 hasConceptScore W1996935761C2780930700 @default.
• W1996935761 hasConceptScore W1996935761C3019892230 @default.
• W1996935761 hasConceptScore W1996935761C71924100 @default.
• W1996935761 hasConceptScore W1996935761C90924648 @default.
• W1996935761 hasIssue "3" @default.
• W1996935761 hasLocation W19969357611 @default.
• W1996935761 hasLocation W19969357612 @default.
• W1996935761 hasLocation W19969357613 @default.
• W1996935761 hasOpenAccess W1996935761 @default.
• W1996935761 hasPrimaryLocation W19969357611 @default.
• W1996935761 hasRelatedWork W1510497893 @default.
• W1996935761 hasRelatedWork W2015677102 @default.
• W1996935761 hasRelatedWork W2027064263 @default.
• W1996935761 hasRelatedWork W2184534421 @default.
• W1996935761 hasRelatedWork W2488200262 @default.
• W1996935761 hasRelatedWork W2563198120 @default.
• W1996935761 hasRelatedWork W2599748425 @default.
• W1996935761 hasRelatedWork W3116441850 @default.
• W1996935761 hasRelatedWork W4230849756 @default.
• W1996935761 hasRelatedWork W2028346583 @default.
• W1996935761 hasVolume "31" @default.
• W1996935761 isParatext "false" @default.
• W1996935761 isRetracted "false" @default.
• W1996935761 magId "1996935761" @default.
• W1996935761 workType "article" @default.